Retsef Levi

Retsef Levi, Elisabeth Paulson, Georgia Perakis et al.

We address a core problem in causal inference: estimating heterogeneous treatment effects using panel data with general treatment patterns. Many existing methods either do not utilize the potential underlying structure in panel data or have limitations in the allowable treatment patterns. In this work, we propose and evaluate a new method that first partitions observations into disjoint clusters with similar treatment effects using a regression tree, and then leverages the (assumed) low-rank structure of the panel data to estimate the average treatment effect for each cluster. Our theoretical results establish the convergence of the resulting estimates to the true treatment effects. Computation experiments with semi-synthetic data show that our method achieves superior accuracy compared to alternative approaches, using a regression tree with no more than 40 leaves. Hence, our method provides more accurate and interpretable estimates than alternative methods.

Jackie Baek, Vivek F. Farias, Andreea Georgescu et al.

This paper provides the first sample complexity lower bounds for the estimation of simple diffusion models, including the Bass model (used in modeling consumer adoption) and the SIR model (used in modeling epidemics). We show that one cannot hope to learn such models until quite late in the diffusion. Specifically, we show that the time required to collect a number of observations that exceeds our sample complexity lower bounds is large. For Bass models with low innovation rates, our results imply that one cannot hope to predict the eventual number of adopting customers until one is at least two-thirds of the way to the time at which the rate of new adopters is at its peak. In a similar vein, our results imply that in the case of an SIR model, one cannot hope to predict the eventual number of infections until one is approximately two-thirds of the way to the time at which the infection rate has peaked. This lower bound in estimation further translates into a lower bound in regret for decision-making in epidemic interventions. Our results formalize the challenge of accurate forecasting and highlight the importance of incorporating additional data sources. To this end, we analyze the benefit of a seroprevalence study in an epidemic, where we characterize the size of the study needed to improve SIR model estimation. Extensive empirical analyses on product adoption and epidemic data support our theoretical findings.